Interview: CNBG vaccine protects against variant coronavirus strains: company chairman

BEIJING, Jan. 15 (Xinhua) -- The inactivated vaccine developed by China National Biotec Group (CNBG) affiliated with Sinopharm is broad-spectrum and can cross-neutralize different coronavirus strains, CNBG chairman Yang Xiaoming told Xinhua in a recent interview.

"Tests for the mutant strains found in Britain are in progress, and the preliminary results are good. It (the vaccine) can induce protection," said Yang.